Third Harmonic Bio, Inc. is a biopharmaceutical company. The Company is focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is developing medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. Mast cells are a part of the immune system, and dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of inflammatory disorders including urticaria, asthma and gastrointestinal disorders, among others. The Company is advancing its lead product candidate, THB335, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway and gastrointestinal tract. THB335 is a potent, highly selective, oral small molecule KIT inhibitor with a promising preclinical product profile.
Ticker SymbolTHRD
Company nameThird Harmonic Bio Inc
IPO dateSep 15, 2022
CEO- -
Number of employees53
Security typeOrdinary Share
Fiscal year-endSep 15
Address1700 Montgomery Street
CitySAN FRANCISCO
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94111
Phone12097272457
Websitehttps://thirdharmonicbio.com/
Ticker SymbolTHRD
IPO dateSep 15, 2022
CEO- -
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data